Skip to main content
logo
Oruka Therapeutics, Inc. (ORKA)
NASDAQ: ORKA · Real-Time Price · USD
103.35
+0.93 (0.91%)
Aug 25, 2026, 11:55 AM EDT - Market open

Oruka Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Net Income
-132.89-105.43-91.34
Depreciation & Amortization
0.130.080.03
Loss (Gain) From Sale of Investments
-3.1-5-2.45
Stock-Based Compensation
28.5324.2416.28
Other Operating Activities
0.560.461.74
Change in Accounts Payable
3.17-5.3210.35
Change in Other Net Operating Assets
2.682.772.3
Operating Cash Flow
-100.92-88.21-63.09
Operating Cash Flow Growth
---

Investing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Capital Expenditures
-0.24-0.21-0.21
Investment in Securities
-569.62-96.54-359.93
Investing Cash Flow
-569.86-96.75-360.14

Financing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Total Debt Issued
--27.25
Net Debt Issued (Repaid)
--27.25
Issuance of Common Stock
873.85170.32459.96
Financing Cash Flow
873.85170.32490.41

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Net Cash Flow
203.07-14.6467.17

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Free Cash Flow
-101.15-88.42-63.3
Free Cash Flow Growth
---
Free Cash Flow Per Share
-1.87-1.94-3.77
Levered Free Cash Flow
-65.03-55.83-
Unlevered Free Cash Flow
-65.03-55.83-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Change in Working Capital
5.84-2.5612.64
SEC Filings: 10-K · 10-Q